1. Deals Analysis
January 20, 2021updated 12 Feb 2021 7:35am

Consumer industry cross border M&A deals total $451.65m in Europe in December 2020

Total consumer industry cross border M&A deals worth $451.65m were announced in Europe in December 2020, led by Thrasio’s $269.69m acquisition of Maximo Fitness, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked a decrease of 90.8% over the previous month of $4.92bn and a drop of 86.9% when compared with the last 12-month average of $3.45bn.

Europe held a 36.42% share of the global consumer industry cross border M&A deal value that totalled $1.24bn in December 2020. With a 25.09% share and deals worth $311.13m, the UK was the top country in Europe’s cross border M&A deal value across consumer industry.

In terms of cross border M&A deal activity, Europe recorded 21 deals during December 2020, marking an increase of 23.53% over the previous month and a drop of 4.55% over the 12-month average. The UK recorded five deals during the month.

Europe consumer industry cross border M&A deals in December 2020: Top deals

Content from our partners
Advanced analytics and predicting market trends in FMCG
How smart predictive analytics is shaping product development
Data analysis in the brave new world

The top five consumer industry cross border M&A deals accounted for 99.9% of the overall value during December 2020.

The combined value of the top five consumer cross border deals stood at $451.16m, against the overall value of $451.65m recorded for the month.

The top five consumer industry cross border M&A deals of December 2020 tracked by GlobalData were:

1) Thrasio’s $269.69m acquisition of Maximo Fitness

2) The $86.5m acquisition of Passoa by Lucas Bols

3) Pollard Banknote’s $44.22m acquisition of Next Generation Lotteries

4) The $41.44m asset transaction with Sportech by BetMakers

5) Vision Healthcare’s acquisition of NaturaMed Pharma for $9.32m.

Topics in this article: